Haleos Labs Limited
SMSLIFE.BO
Bombay Stock Exchange1,560.10
INR
-108.90
- -
Haleos Labs Limited
SMSLIFE.BO
(Bombay Stock Exchange)
Recent
price
1,560.10
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- SMS Lifesciences India Limited operates primarily in the pharmaceutical and life sciences sector, specializing in the manufacturing and marketing of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and specialty chemicals. The company’s product portfolio encompasses a wide range of APIs including oncology, cardiovascular, and anti-diabetic segments; pharmaceutical intermediates; and custom synthesis services for global pharmaceutical clients. It also offers contract research and manufacturing services (CRAMS) to the pharmaceutical industry. Founded in 1981 and headquartered in Ahmedabad, India, SMS Lifesciences has a significant presence in domestic and international markets, serving pharmaceutical companies across Asia, Europe, and the Americas. Recently, the company has focused on strategic expansion through enhancing its manufacturing capacities and forming partnerships to strengthen its global supply chain. It has introduced new specialty chemical lines and expanded its research and development capabilities to innovate in high-growth therapeutic areas. These initiatives reflect a deliberate move towards integrated life sciences solutions, positioning SMS Lifesciences as a diversified and expanding entity in the pharmaceutical manufacturing sector. The company operates through various business segments including Pharma Formulations, APIs, and specialty chemicals, targeting pharmaceutical manufacturers, healthcare providers, and research institutions. It continues to invest in compliance and quality certifications to meet stringent regulatory standards globally. The recent strategic shifts include entering new geographic markets and enhancing vertical integration to optimize production and supply efficiency. SMS Lifesciences India Limited remains independent with no widely publicized parent company relationships and continues to leverage its established manufacturing infrastructure across multiple sites in India to maintain its competitive edge. The company’s focus on innovation, expansion of its product lines, and operational excellence underpin its growth strategy in the evolving pharmaceutical landscape.